SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, especially accelerating AI-compute revenue, sparked analyst upgrades and a bullish response. Traders also debated whether growth justifies the valuation, with heavy capital spending and an approaching share unlock cited as potential risks; Tesla merger discussions remain speculative.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings report beat profit expectations, but softer forward revenue guidance and a reduced advertising outlookalongside slowing growthtriggered a sharp selloff and renewed analyst downgrades. Traders are split between viewing the drop as evidence of tougher competition and weaker growth, and calling it an overreaction that creates a buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook was sharply raised on strong AI-server demand, with gross-margin expectations also improving, sparking a sharp rally. Traders largely welcomed the update and argued the stock is undervalued, while others questioned whether margins, cash flow and execution can sustain the gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th-event trigger and final analysis of its Phase 3 REGAL trial of GPS in AML, with recent trading gains fueling speculation about a near-term update and a possible short squeeze. Bullish buyout and positive-data theories are prominent, but skeptics note that no catalyst or outcome is confirmed and the trial results remain uncertain.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs spectrum acquisition and plans to expand Starlink Mobile have fueled concern that it could challenge AT&T and other wireless carriers, contributing to a sharp telecom selloff. Traders debate whether the threat is meaningful or years away, with bulls calling the drop an overreaction and pointing to AT&Ts fiber network and dividend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on preliminary Phase 1 azer-cel results in progressive multiple sclerosis, with traders viewing the early safety and efficacy signals as a potential pipeline expansion beyond BRIUMVI while emphasizing that the study is small and needs confirmation. BRIUMVIs longer-term and commercial data also feature in the discussion, alongside mixed reactions to the stocks lack of sustained momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

FDA approval of ORLADEYO oral pellets is drawing attention, with traders viewing the easier-to-administer formulation as a possible way to reach more HAE patients and improve tolerability. Some see incremental commercial potential, while others doubt it will meaningfully affect the share price amid continued frustration with BCRXs underperformance and management.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Analyst downgrades citing lackluster October momentum are weighing on Chipotle shares as traders look ahead to earnings amid concerns about slowing sales and margins. The community is split between expecting further declines and viewing the selloff as a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Speculation about possible U.S. regulatory relief for compounded peptides is a dominant topic, with bullish traders viewing access as a potential growth opportunity and skeptics emphasizing that approval is uncertain. The debate plays out alongside frustration over repeated rallies fading at resistance, while Hims German expansion adds to the growth discussion.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkors strong quarterly results have been overshadowed by a softer-than-expected revenue outlook, alongside a broader semiconductor selloff. Traders are split between viewing the decline as an overreaction to near-term guidance and worrying about AI demand, expansion costs, and whether advanced-packaging growth will justify the investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 411,325 shares, an increase of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the company's shares are...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts

Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the stock, MarketBeat...

Analysts Offer Predictions for Adagene FY2026 Earnings

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share fo...

Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price

Guggenheim raised their price target on Adagene from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday...

Why Is ADAG Stock Tanking Today?

Equity

Adagene priced the public offering of its American depository shares at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday.

Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS

Adagene (NASDAQ:ADAG - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28...

Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6%

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 74,016...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are currently covering the company, Marketbeat reports. One...

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Adagene Inc - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Adagene also announced an update from the Phase 1b/2 study of Muzastotug in combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer with no liver metastases.</li><li>The company stated that the results show an improved durability of response among patients in the trials.</li><li>Adagene added that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the FDA.</li></ul>Adagene Inc. (ADAG) shares tanked nearly 10% in Thursday’s opening trade after the company announced a slew of updates, including the pricing of a $70 million public offering of its American depository shares.Adagene priced the public offering at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday. The offering is expected to close on April 6, 2026.Adagene also announced an update from the Phase 1b/2 study of Muzastotug in Combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer (MSS CRC) with no liver metastases. The company stated that the results show an improved durability of response among patients in the trials.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ADAG">Adagene</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Adagene Provides Update On Muzastotug Trials</h2>The company stated that Muzastotug, in combination with Merck’s Keytruda, achieved an overall response rate (ORR) of 31% in the combined 20 mg/kg dose cohort, compared to an ORR of 13% in the 10 mg/kg dose cohort.Adagene added that the median duration of response (mDOR) has not yet been achieved in the 20 mg/kg dose cohort, with responses ongoing beyond 9 months. However, the 10 mg/kg dose cohort achieved an mDOR of 6.2 months.The Progression-Free Survival (PFS) stood at 6.7 months in the 20 mg/kg cohort, outlasting the 4.8 months observed in the 10 mg/kg dose cohort, according to the company.Adagene stated that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).In the 10 mg/kg cohort, the median overall survival was 19.8 months, with 48% of patients alive at two years. In the 20 mg/kg cohort, one-year survival was 80.8%, compared with 70.1% in the 10 mg/kg cohort.The company added that there was a 4% discontinuation rate across the two doses, and that there were no dose-limiting toxicities observed.<h2 class="st-heading-2">Adagene Teams Up With Incyte</h2>Adagene stated that it has partnered with Incyte Corp. (INCY) to evaluate the combination of muzastotug and INCA33890 in patients with MSS CRC with or without liver metastases.The company added that as a monotherapy, INCA33890 has demonstrated promising clinical efficacy and safety in immune checkpoint sensitive and insensitive cancers, including MSS CRC with and without liver metastases.<a href="https://stocktwits.com/symbol/ADAG">ADAG stock</a> is up 130% year-to-date. The Invesco Golden Dragon China ETF (PGJ) is down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-march-2026/cZ7xoOYRI8R">Tesla’s China-Made EV Sales Rise 9% In March, Registering Fifth Straight Month Of Gains: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Invesco Golden Dragon China ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

ADAG Adagene Inc - ADR

Fundamentals

Latest ADAG News